Synthesis, modelling and kinetic assays of potent inhibitors of purple acid phosphatase
作者:Siti Hajar Mohd-Pahmi、Waleed M. Hussein、Gerhard Schenk、Ross P. McGeary
DOI:10.1016/j.bmcl.2011.03.024
日期:2011.5
Purpleacidphosphatases (PAPs) are binuclear metallohydrolases that have been isolated from various mammals, plants, fungi and bacteria. In mammals PAP activity is associated with bone resorption and can lead to bone metabolic disorders such as osteoporosis; thus human PAP is an attractive target to develop anti-osteoporotic drugs. Based on a previous lead compound and rational drug design, acyl derivatives
紫色酸性磷酸酶(PAP)是双核金属水解酶,已从各种哺乳动物,植物,真菌和细菌中分离出来。在哺乳动物中,PAP活性与骨吸收有关,并可能导致骨代谢紊乱,例如骨质疏松。因此,人PAP是开发抗骨质疏松药物的有吸引力的靶标。基于先前的先导化合物和合理的药物设计,合成了α-氨基萘基甲基膦酸的酰基衍生物并作为PAP抑制剂进行了测试。动力学分析表明它们是良好的PAP抑制剂,其效力随着酰基链长度的增加而提高。当酰基链中的碳原子数在12和14之间时,可以达到最大效价。最有效的红芸豆PAP抑制剂是带有K ic的十二烷基衍生物 = 5μM,而最有效的猪PAP抑制剂是十四烷基衍生物,K ic = 8μM,这是迄今报道的哺乳动物PAP的最有效抑制剂。